우리나라 성인에서 Haemophilus influenzae type b에 대한 항체 평가 = Evaluation of Antibodies Against Haemophilus influenzae Type b in Korean Adults

다국어 초록 (Multilingual Abstract)

Purpose: After the introduction of Haemophilus influenzae type b (Hib) vaccine in 1995 in Korea, it was included in the national immunization program in 2013. In the post-Hib vaccine era, some studies in other countries reported that invasive Hib disease affects adults, especially the elderly and immunocompromised persons, more often than it affects children. To evaluate disease susceptibility, quantitative and qualitative analysis of anti-polyribosylribitol phosphate (PRP) antibodies were carried out in Korean adults aged 20 to 85 years.
Methods: Sera were collected from 39 healthy adults (20 to 50 years of age) and from 30 elderly adults (75 to 85 years of age) who did not have immune-compromising conditions. The concentration of anti-PRP immunoglobulin G (IgG) and serum bactericidal indices (SBIs) were measured by enzyme-linked immunosorbent assay and serum bactericidal assay.
Results: Geometric mean concentrations of anti-PRP IgG and geometric mean SBIs were 0.88 μg/mL (95% confidence interval [CI], 0.17 to 3.85) and 354 (95% CI, 50 to 2,499) in young adults and 1.67 μg/mL (95% CI, 0.53 to 5.24) and 449 (95% CI, 146 to 1,376) in elderly adults, respectively. When the threshold of seropositivity for anti-PRP IgG was applied as 0.15 or 1.0 μg/mL, which is the protective antibody level in children, seropositive rates were 87.2% or 53.8% in young adults and 100% or 60% in elderly adults. The seropositivity rates of the SBI (SBI ≥4) were 82.1% and 100% in the groups, respectively.
Conclusions: Most subjects in the adult and elderly adult groups display immunity to Hib based on quantitative and qualitative antibody levels, but not all. Because high immunization and low Hib circulation rates may reduce the natural Hib immunity in the population, monitoring Hib immunity as well as disease are needed continuously.

국문 초록 (Abstract)

목적: 1995년 한국에서 b형 헤모필루스 인플루엔자(Haemophilus influenzae type b [Hib]) 백신이도입된 이후, 2013년 국가예방접종에 포함되었다. Hib 백신 도입 시기 이후 다른 나라의 일부 연구에따르면, 침습적 Hib 질환은 소아보다 성인, 특히 노인 및 면역 저하 환자에서 더 자주 발생한다고 보고하였다. 따라서, 본 연구는 20–85세의 한국 성인에서 항-polyribosylribitol phosphate (PRP) 항체의 양적 및 질적 측정을 통하여 질병 감수성을 평가하고자 하였다.
방법: 혈청은 39명의 건강한 성인(20–50세)과 면역 저하 상태가 아닌 30명의 노인(75–85세)에서 수집하였다. 모든 피험자는 7일 이내에 항생제를 복용하지 않았다. 항-PRP 면역글로불린 G (immunoglobulin G [IgG]) 항체가 및 혈청 살상능 역가(serum bactericidal index [SBI])는 효소결합면역흡착측정법과 혈청 살상능 평가분석을 통해 측정하였다.
결과: 항-PRP IgG 항체가의 기하평균 및 SBI의 기하평균은 성인군에서 각각 0.88 μg/mL (95% 신뢰구간, 0.17–3.85) 및 354 (95% 신뢰구간, 50–2,499)이었고, 노인군에서는 각각 1.67 μg/mL (95% 신뢰구간, 0.53–5.24) 및 449 (95% 신뢰구간, 146–1,376)이었다. 소아에서 Hib 감염에 대한 방어농도로 인정하고 있는 0.15 및 1.0 μg/mL을 적용하였을 때, 항체 양성률은 성인군에서 87.2%, 노인군에서 100%였다. SBI의 양성률(SBI ≥4)은 성인군에서 82.1%, 노인군에서 100%였다.
결론: 대부분의 성인군과 노인군에서 양적으로나 기능적으로 Hib 질환에 대한 방어 면역력을 가지고있었으나 모두는 아니었다. 높은 면역력과 낮은 Hib 순환율은 인구에서 Hib에 대한 자연면역을 감소시킬 수 있으므로, Hib 면역과 질병에 대한 지속적인 감시가 필요하다.

참고문헌 (Reference)

1 Pittman M, "Variation and type specificity in the bacterial species Hemophilus influenzae" 53 : 471-492, 1931

2 Chandran A, "Vaccines" Elsevier Health Sciences 167-182, 2013

3 McVernon J, "Trends in Haemophilus influenzae type b infections in adults in England and Wales : surveillance study" 329 : 655-658, 2004

4 Kayhty H, "The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b" 147 : 1100-, 1983

5 Dworkin MS, "The changing epidemiology of invasive Haemophilus influenzae disease, especially in persons > or = 65 years old" 44 : 810-816, 2007

6 Oh SY, "School-aged children : a reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom" 197 : 1275-1281, 2008

7 Nix EB, "Risk of invasive Haemophilus influenzae type b(Hib)disease in adults with secondary immunodeficiency in the post-Hib vaccine era" 19 : 766-771, 2012

8 Chew CG, "Relapsing CAPD peritonitis with rapid peritoneal sclerosis due to Haemophilus influenzae" 12 : 821-822, 1997

9 Shinefield HR, "Postlicensure surveillance for Haemophilus influenzae type b invasive disease after use of Haemophilus influenzae type b oligosaccharide CRM197conjugate vaccine in a large defined United States population : a four-year eight-month follow-up" 14 : 978-981, 1995

10 Song JY, "Pneumococcal vaccine and opsonic pneumococcal antibody" 19 : 412-425, 2013

11 Saito T, "Necrotizing fasciitis caused by Haemophilus influenzae type b in an elderly patient" 47 : 852-854, 2009

12 Chalmers C, "Necrotising fasciitis complicating Haemophilus influenzae type b epiglottitis in an adult" 124 : 807-809, 2010

13 Collins S, "Invasive Haemophilus influenzae type b disease in England and Wales: who is at risk after 2 decades of routine childhood vaccination?" 57 : 1715-1721, 2013

14 Shuel M, "Invasive Haemophilus influenzae in British Columbia: non-Hib and nontypeable strains causing disease in children and adults" 15 : e167-e173, 2011

15 Rubach MP, "Increasing incidence of invasive Haemophilus influenzae disease in adults, Utah, USA" 17 : 1645-1650, 2011

16 Skoff TH, "Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990-2007" 49 : 85-92, 2009

17 Mackenzie GA, "Increased disease due to Haemophilus influenzae type b: population-based surveillance in eastern Gambia, 2008-2013" 34 : e107-e112, 2015

18 조혜경, "Impact of IgM Antibodies on Cross-Protection against Pneumococcal Serogroups 6 and 19 after Immunization with 7-Valent Pneumococcal Conjugate Vaccine in Children" 대한의학회 31 (31): 950-956, 2016

19 김경호, "Immunogenicity and Safety of Two Different Haemophilus influenzae Type b Conjugate Vaccines in Korean Infants" 대한의학회 23 (23): 929-936, 2008

20 Lee H, "Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A" 16 : 376-381, 2009

21 김경효, "Haemophilus influenzae type b(Hib) 백신 접종의 현황과 전망" 대한소아과학회 49 (49): 242-250, 2006

22 김경효, "Haemophilus influenzae type b 피막 다당질 특이 인간 IgG 항체의 정량적 측정을 위한 enzyme immunoassay의 타당성 연구" 대한소아과학회 50 (50): 143-150, 2007

23 Peltola H, "Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland" 60 : 730-737, 1977

24 Neuhaus TJ, "Haemophilus influenzae : a cause of peritonitis in peritoneal dialysis" 11 : 199-200, 1996

25 World Health Organization, "Guidelines on clinical evaluation of vaccines: regulatory expectations" World Health Organization

26 Edwards MS, "Group B streptococcal infections in elderly adults" 41 : 839-847, 2005

27 Watt JP, "Global reduction of Hib disease: what are the next steps? Proceedings of the meeting Scottsdale, Arizona, September 22-25, 2002" 143 (143): S163-S187, 2003

28 Jelonek MT, "Comparison of naturally acquired and vaccineinduced antibodies to Haemophilus influenzae type b capsular polysaccharide" 61 : 5345-5350, 1993

29 Public Health Agency of Canada, "Canadian immunization guide 2006"

30 김예진, "Antibody Responses in Hematopoietic Cell Transplantation Recipients after Vaccination Against Haemophilus Influenzae Type b and Streptococcus pneumoniae" 대한소아감염학회 21 (21): 81-95, 2014

31 Idoko OT, "Antibodies against Haemophilus influenzae type b in The Gambia : investigating the extent of protection across age groups" 32 : 4620-4624, 2014

32 Kim HW, "A high throughput serum bactericidal assay for antibodies to Haemophilus influenzae type b" 16 : 473-, 2016